- BRAFTOVI -

A BREAKTHROUGH IN OVERALL SURVIVAL

From a Phase 3 trial in BRAFv600E-mutant mCRC

Image
Home page banner Braftovi


BRAFTOVI + CETUXIMAB

BRAFTOVI is indicated in combination with cetuximab, for the treatment of adult patients with metastatic colorectal cancer (CRC) with a BRAF V600E mutation, who have received prior systemic therapy.1

Image
Braftovi encorafenib

Presentation

BRAFTOVI (encorafenib) is a targeted therapy that demonstrates, in combination with cetuximab, a breakthrough in overall survival.1 BEACON CRC, the only Phase 3 trial to exclusively study patients with BRAFV600E-mutant mCRC, demonstrates unprecedented OS and ORR results for these patients.3

Based on BEACON CRC data, the European Commission approved BRAFTOVI for patients with BRAFV600E-mutant mCRC, who have received prior systemic therapy.1

BRAFTOVI regimen provides an actionable reason to test all patients with mCRC for a BRAFV600E  mutation at diagnosis.

Image
our objectives

Choose BRAFTOVI + cetuximab for your patients with BRAFV600E-mutant mCRC, who have received prior systemic therapy


BRAFTOVI + cetuximab provide an actionable reason to test all patients with mCRC for BRAFV600E mutation at diagnosis1

* OS: 9.3 months (95% CI: 8.0-11.3) vs 5.9 months (95% CI: 5.1-7.1) with FOLFIRI + cetuximab or irinotecan + cetuximab (HR=0.61 [95% CI: 0.48-0.77], P<0.0001)
ORR 19.5% (95% CI: 14.5-25.4) with BRAFTOVI + cetuximab vs 1.8% (95% CI: 0.5-4.6) with FOLFIRI + cetuximab or irinotecan + cetuximab (P<0.0001)
** Rate of discontinuation primarily due to AEs (any grade) was 8% with BRAFTOVI + cetuximab compared to 11% with FOLFIRI + cetuximab or irinotecan + cetuximab.
*** The most common (≥25%) AEs (any grade) reported with BRAFTOVI + cetuximab were nausea, diarrhoea, fatigue, acneiform dermatitis, and decreased appetite

HealthCare Professionals​

This is an international website for BRAFTOVI dedicated to Healthcare professionals ​​

IMPORTANT: the information on this website is based on the European Summary of Product Characteristics. Prescribing Information and indication may vary per country. You must refer to your country prescribing information. Please be aware we do not take responsibility for accessing such information which may not comply with the regulation or usage in your country.

I certify that:

I am Healthcare Professional outside the US and I have read the information above​. 

Patients

This is an international website for BRAFTOVI dedicated to Healthcare professionals.

I am a patient outside the US​